ArriVent BioPharma, Inc. (AVBP) vs Olema Pharmaceuticals, Inc. (OLMA)
A side-by-side comparison of ArriVent BioPharma, Inc. and Olema Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.09HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
OLMA
Olema Pharmaceuticals, Inc.
$7.85HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — AVBP vs OLMA
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)OLMA -28.2% (-10.5%/yr)AVBP compounded faster over this window
AVBP OLMA
AVBP vs OLMA: by the numbers
- •AVBP is the larger company ($703M vs $686M market cap).
Metrics side by side
Valuation
| Metric | AVBP | OLMA |
|---|---|---|
| P/B ratio | 1.92 | 1.59 |
Profitability
| Metric | AVBP | OLMA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -44.63% | -47.51% |
| ROIC | -47.96% | -50.92% |
Growth (annualized)
| Metric | AVBP | OLMA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -21.50% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.